Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
22.35
+0.24 (1.09%)
May 28, 2026, 2:27 PM EDT - Market open
Immunome Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Immunome stock has a consensus rating of "Strong Buy" and an average price target of $35.36. The average 1-year stock price forecast is 58.21% higher than the current stock price, while the lowest is $30 (+34.23%) and the highest is $40 (+78.97%).
Price Target: $35.36 (+58.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 12 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Supawat Thongthip Truist Financial No rating | Truist Financial | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +65.55% | May 28, 2026 |
Unknown Analyst Barclays No rating | Barclays | Buy Initiates $36 | Buy | Initiates | $36 | +61.07% | May 28, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $40 | Buy | Maintains | $40 | +78.97% | May 16, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $37 → $33 | Buy | Maintains | $37 → $33 | +47.65% | May 15, 2026 |
| Lake Street | Lake Street | Buy Maintains $30 | Buy | Maintains | $30 | +34.23% | May 14, 2026 |
Financial Forecast
Revenue This Year
4.74M
from 6.94M
Decreased by -31.78%
Revenue Next Year
84.14M
from 4.74M
Increased by 1,677.00%
EPS This Year
-2.39
from -2.43
EPS Next Year
-2.16
from -2.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 27.9M | 227.2M | ||||||
| Avg | 4.7M | 84.1M | ||||||
| Low | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 302.4% | 4,698.3% | ||||||
| Avg | -31.8% | 1,677.0% | ||||||
| Low | - | 44.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.19 | -1.31 | ||||||
| Avg | -2.39 | -2.16 | ||||||
| Low | -2.76 | -2.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.